Coverage restrictions likely to apply to recently-approved ANCA vasculitis drug
Payers will likely use restrictions seen with other rare diseases when it comes to ChemoCentryx’s recently approved AAV drug.
Drug Development
FDA approves mixing of newly approved Covid-19 booster shots
The US FDA approved the 'mixing and matching' of Covid-19 vaccine booster shots, which will...
Boehringer Ingelheim and Thoeris to work on urea cycle disorder therapies
Boehringer Ingelheim will contribute its research and drugs development expertise for advancing medications into the...
FDA approves Bausch + Lomb and Clearside’s macular oedema treatment
The SCS Microinjector provides exclusive access to the eye’s back portion, which is often the...
Merck’s Keytruda obtains EC approval for breast cancer
With the approval, the combination treatment will be marketed in all 27 member states of...
Merck’s molnupiravir: Covid-19 gamechanger status relies on patient risk factors
Molnupiravir access may depend on how risk factors are interpreted but availability could be wider with the help of pharmacists
EC grants approval to BMS’ Opdivo combo for gastroesophageal cancer
In a Phase III trial, Opdivo plus chemotherapy offered statistically significant improvement in overall survival.
Inovio signs MoU with Colombia to boost efforts to tackle Covid-19
The MoU will aid in creating production expertise for Inovio’s DNA drugs and technologies in the country.
Biotage signs agreement to acquire UK’s ATDBio
Merging ATDBio’s oligonucleotide production skills with the one-stop-shop customer workflow of Biotage offers high potential.
UK government secures two Covid-19 antivirals ahead of winter
The purchase of Merck and Pfizer’s Covid-19 pills comes as coronavirus cases and hospitalisations rise across the country.
PTF: The ethics of vaccine boosters
In this issue: The ethical dilemma of vaccine boosters, optimising real-world data in the pharma industry, billionaires search for ways to cure ageing, predicting the placebo response, and much more.
